Kailera Therapeutics, Inc. (NASDAQ:KLRA) Stock Rated “Moderate Buy” by Wall Street Analysts

Kailera Therapeutics, Inc. (NASDAQ:KLRA) has earned an average recommendation of “Moderate Buy” from the eight analysts that are presently covering the stock, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has given a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price objective among brokerages that have issued ratings on the stock in the last year is $42.75.

Separately, Weiss Ratings raised Kailera Therapeutics from a “sell (d-)” rating to a “sell (d)” rating in a research report on Wednesday, October 21st.

Kailera Therapeutics Stock Performance

Shares of KLRA opened at $12.97 on Tuesday. The stock has a market cap of $1.68 billion and a price-to-earnings ratio of -0.00. The company’s fifty day moving average is $12.78. Kailera Therapeutics has a 1-year low of $9.76 and a 1-year high of $28.23.

Kailera Therapeutics (NASDAQ:KLRA) last released its quarterly earnings results on Wednesday, November 4th. The company reported ($0.74) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.55) by $0.81. Research analysts expect that Kailera Therapeutics will post -3.89 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Kailera Therapeutics

Several institutional investors have recently made changes to their positions in the business. Frazier Life Sciences Management L.P. bought a new position in Kailera Therapeutics in the 2nd quarter worth $24,233,000. State Street Corp purchased a new position in Kailera Therapeutics during the second quarter valued at $19,126,000. Atlas Venture Life Science Advisors LLC purchased a new position in Kailera Therapeutics during the second quarter valued at $113,923,000. Wellington Management Group LLP bought a new stake in Kailera Therapeutics during the second quarter valued at about $64,308,000. Finally, Mirador Capital Partners LP bought a new stake in Kailera Therapeutics during the third quarter valued at about $666,000.

Kailera Therapeutics Company Profile

Kailera Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and related metabolic diseases.

The company’s activities center on the research and development of potential pharmaceutical therapies intended to address chronic weight management and associated health conditions. Its products remain in development and are subject to clinical, regulatory and commercial milestones.

Publicly available information about Kailera Therapeutics’ specific product candidates, operating geographies and leadership is limited.